Biliary Tract Cancer Clinical Trial
Official title:
Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer
This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.
Biliary tract cancers (BTC) includes cholangiocarcinoma and gallbladder carcinoma (GBC). The
systematic treatment based on gemcitabine plus cisplatin is recommended as the current
standard chemotherapy for unresectable or metastatic BTC. There is no standard
recommendation for second line therapy.
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor
receptor 2(VEGFR-2).
This study was conducted to assess the efficacy and safety of Apatinib in patients with
advanced refractory BTC who had received first-line chemotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Withdrawn |
NCT03110510 -
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
|
Phase 2 | |
| Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00380588 -
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Terminated |
NCT00090025 -
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
|
Phase 3 | |
| Terminated |
NCT04066491 -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05998447 -
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT03718897 -
Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
|
||
| Recruiting |
NCT05056116 -
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
|
N/A | |
| Recruiting |
NCT04692051 -
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Terminated |
NCT04057365 -
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
|
Phase 2 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
| Recruiting |
NCT04584996 -
CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
|
||
| Completed |
NCT02579616 -
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT05052099 -
Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01494363 -
Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT00753675 -
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
|
Phase 2 | |
| Terminated |
NCT00630890 -
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
|
Phase 1 | |
| Recruiting |
NCT04445532 -
Hepatobiliary Tumors Tissue Samples Acquisition
|